10 December 2025 – Hong Kong. DualityBio (Stock Code: 9606.HK) announced that its shares have been included as a constituent of the Hong Kong Exchange TECH-100 Index (HKEX TECH-100), following the index launch announced by Hong Kong Exchanges and Clearing Limited (HKEX) on 9 December.

Concurrently, according to the adjustment list published by FTSE Russell on 4 December, DualityBio has also been included as a constituent of the FTSE China Small Cap Index as part of the quarterly review of the FTSE Global Equity Index Series (FTSE GEIS), which will take effect after the market close on 19 December 2025.

The Hong Kong Exchange TECH-100 Index is designed to track the performance of the 100 largest eligible Hong Kong-listed securities with high exposure to technology-related themes and Stock Connect eligibility. It aims to capture growth opportunities within technology trends, respond to the market's demand for diversified exposure to the technology sector, and provide investors with expanded investment choices. Index constituents cover industry leaders and emerging companies across six technology domains: Artificial Intelligence (AI), Biotechnology & Pharmaceuticals, Electric Vehicles & Smart Driving, Information Technology, Internet, and Robotics. This also includes biotech companies listed under Chapter 18A and specialist technology companies listed under Chapter 18C of the HKEX Listing Rules.

Dr. John Zhu, Founder and CEO of DualityBio, stated: “Since DualityBio’s listing on the Hong Kong Stock Exchange in April, this inclusion in both the HKEX TECH-100 Index and the FTSE China Small Cap Index represents a recognition from the capital markets of our corporate performance and value. It is also a strong endorsement of our core technological attributes and innovative achievements, and we are deeply proud of this milestone. DualityBio will continue to lead innovation in the field of BIO + TECH, striving to bring more breakthrough therapies to patients globally and contribute to the globalization of China’s pharmaceutical industry.”

About DualityBio

Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 20 countries and has enrolled over 2,700 patients for multiple clinical-stage ADC candidates.

Additionally, DualityBio has established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.

For more information, please visit: www.dualitybiologics.com.

Media Contact: PR@dualitybiologics.com

Investor Contact: IR@dualitybiologics.com